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The comment from Lin et al.1 raises a very interesting and
often neglected issue, that while looking for the biomarker
needle in the haystack of candidate molecules, characteri-
zation of the experimental signal is often neglected. In the
quest for classifiers of disease among multiple candidate
markers, which sometimes gets the derogatory description
of ‘fishing expedition’, the emphasis is narrowly placed on
discrimination. This is a pragmatic approach that is ideally
validated by comparing predictions and observations for
external data sets. As obviously important as this
validation seems, it has not been successfully done for
any identified set of plasma or urine protein biomarkers
discovered using proteomic techniques. Validation is hard
enough as the ‘blindness’ of external testing may be biased
by lack of independence between the training and testing
data sets.2 Therefore, in our opinion, the twin issues of
calibration and discrimination can be safely reported
separately as we did.3 The calibration methodology, which
relies on non-parametric normalization, is referenced in
the Methods section to an earlier report by us.4 We
nevertheless agree that this is not reason enough not to
explicitly document at least the reproducibility of the
signal to be used as a reference for the reproducibility
reported for the prediction. Before conceding this point a
few considerations are in order when comparing the two,
as calibration might muddy rather than clarify the issue of
predictability.
Predictability can be accessed simply and objectively by
comparing false and true positive classifications for the
range of decision threshold values. This exercise will
produce the well-established Receiver Operator Characteris-
tics curves5 used in our report. The main challenge there is
to do so with a truly independent external data set. On the
contrary, as regards the calibration of a multivariate signal,
one can only provide a straightforward answer as regards
the technical/methodological variability – for example, that
obtained by analyzing the same sample repeated times. The
biological variability is an entirely different matter, as the
predictive signal may rely not on the variation of
individual variables (candidate markers) but on the co-
variation of multiple markers (biomarker patterns). The
classical illustration of this point is the XOR (exclusive OR
signal). Let us imagine a variable that is observed with
unpredictable value in a population as regards being high
or low in the disease vs healthy subgroup. Now let us
imagine a second variable that is a function of the first and
it is the shape of this function that is distinct between the
disease and healthy subgroups. That would cause the
second variable to appear to be as unpredictive as the first
when analyzed individually, while a classifier could be
identified that used the relationship between the two to
accurately predict the disease state. Even in the case the
distribution of values in the general population changes
with time, for example owing to changes in life style, if the
predictive co-variation is rooted on physiological mechan-
isms, the predictive model could, in principle, remain
insensitive to those changes.
Our recent reporting on potential biomarkers for lupus
nephritis is based on a survey of urine proteins in only 20
patients in a single institution, definitely not a clinical
trial. As your correspondent rightly notes, quoting from
Matheny et al. where a 5216 patient data set was analyzed,6
blind reliance on our report to classify new patients is not
advisable not only because different laboratory practices
may introduce changes in measured values but also
because the populations themselves may be very distinct.
Similarly to that report, our identification of predictive
models also relied on resampled cross-validation (we
followed, and referenced, the guidelines for neural network
model identification we previously proposed7). In spite of
the shortcomings of the report (and the field in general),
the study achieved the goal of identifying candidate
markers that could be used for biopsy-free classification
of lupus nephritis. These markers can now be confirmed
using more reproducible and rapid assays to determine if
they hold up in larger sets of patients.
In a nutshell, we agree with the suggestion of Lin, Chiu
et al. as regards documentation of technical variability/
calibration when reporting accuracy in predictions based
on proposed markers. Nevertheless, for an audience with a
pragmatic interest in making predictions about disease
states, it appears that the litmus test should remain with
proving that it works for an external data set.
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p-Cresol for better or worse: But
what are we measuring?
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To the Editor: In a recent paper by Ujhelyi et al.,1 it is
suggested that the decreased antioxidant capacity of plasma ultra-
filtrate observed after a hemodialysis session is related to the
removal of several protein-bound uremic toxins. Although
the authors must be granted for their well-considered methodo-
logical approach, several objections could be raised.
Firstly, it has been demonstrated recently that p-cresol
largely circulates in the form of its conjugate p-cresyl
sulfate2,3 (and a small fraction of p-cresyl glucuronide). This
is of critical importance for in vitro research. The concentra-
tion of unconjugated p-cresol used by Ujhelyi et al. exceeds
in vivo levels by at least a factor 10. Secondly, the percentage
of deconjugation of phenolic compounds depends on the
used analytical procedure and should be taken into account
when comparing results of different methods. Less complete
deconjugation most probably explains the low reported free
p-cresol levels (Table 1). Thirdly, the authors report normal-
ization of free p-cresol levels following a single hemodialysis
session. This finding is counterintuitive, given the fact that
p-cresol circulates as both free and protein bound, and
contrasts with our experience. Indeed, we observed a
reduction ratio of free p-cresol that is only slightly higher
than the reduction ratio of total p-cresol (Table 1).
Finally, although this paper suggests a protective anti-
oxidative effect from elevated p-cresol concentrations in vitro,
we very recently reported data suggesting a deleterious effect
in vivo. Indeed, higher than average free serum levels of
p-cresol predict mortality in hemodialysis patients.4
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We are grateful to Meijers et al.1 for the comments on the
dialytic removal of several protein-unbound metabolites
that decrease the antioxidant capacity of plasma ultrafil-
trate assessed by heme-mediated low-density lipoprotein
(LDL) oxidation and subsequent endothelial cell reac-
tions.2 The recent results on the limited removal of
p-cresol and its conjugates by hemodialysis3,4 have
utmost importance in further development of detoxifying
methods.
The decreased antioxidant capacity of plasma ultrafil-
trate after hemodialysis was demonstrated to occur as a
consequence of the intradialytic removal of L-ascorbic acid,
bilirubin, 3-indoxyl sulfate, indoxyl-b-D-glucuronide,
p-cresol, phenol, and uric acid.2 Other retention solutes –
L-arginine, creatinine, 2-furoic acid, guanidines (guani-
dine, methylguanidine, b-guanidinopropionic acid,
a-guanidinobutyric acid), hippuric acid, myo-inositol,
oxalic acid, polyamines (spermine, spermidine, putrescine,
Table 1 | Comparison between measured p-cresol levels
Reference
Ujhelyi et al. Martinez et al. De Loor et al.
Debrecen Stanford Leuven
Serum total p-cresol
Healthy volunteers (n) 2.271.9 (4) 1.970.4 (29)
HD patients (n) 24.776.3 (19) 24.375.0 (86)
Detected conjugates (%)
p-Cresyl sulfate 100 95.571.1
p-Cresyl glucuronide 0 3.871.8
Unconjugated BLQ BLQ
Serum unbound p-cresol
Before dialysis (n) 0.6070.43 1.93a 1.8671.27 (7)
After dialysis (n) 0.0870.07 0.86a 1.0970.49 (7)
Reduction ratio
Total p-cresol 0.27 0.26 (7)
Free p-cresolb 0.87 0.55 0.41 (7)
BLQ, below limit of quantification; HD, hemodialysis.
All reported data were calculated towards corresponding concentrations of p-cresol
(mg/l).
aValues were calculated from reported percentages of mean values.
bFree p-cresol reduction ratios were estimated by calculation from reported means.
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